Invitation
& Abstract Preparation
Contributions
in any areas of pharmacy, or basic (pre-clinical) or clinical pharmacology or neurosciences research are invited
for presentation at the conference either as oral communication (podium)
or poster presentation. Submissions for research sessions should relate
to original, previously unpublished work contributing to the understanding,
or development of pharmacological science, neurosciences or teaching. In addition, there will be the
traditional Young Scientist sessions where presenters will compete for
the Young Scientist Awards (please view for more information).
Submissions
for research will be adjudicated on the basis of clearly outlining the
research methodology used and with conclusions that are supported by
the described findings. Submissions that represent novel and interesting
research approaches but which may still be incomplete, may be acceptable
as research in progress, where the author indicates that category on
the abstract submission form. The adjudicating panel will make the final
decision on the category in which the abstract is accepted and the form
of presentation method. However, please indicate on the online abstract submission form which
method of presentation you prefer, i.e. either poster or podium presentation. The final decision on the presentation format lies with the Scientific Committee.
The
deadline for submission is 30 June 2011.
The
corresponding author will receive notification of acceptance
by the 1 August 2011.
| Size: |
The
full abstract should be no longer than one A4 page;
margins = 2.54 cm |
| Font: |
Times
New Roman; text size 12 unless otherwise specified. |
| Title: |
Bold
Text in Upper and Lower Case, font size 14, centred. |
| Authors: |
First
name and Surname of each author, bold, font size 12, centred.
Presenting author’s name to be underlined. |
| Affiliations: |
Name
of department and institution, font size 10, bold, centred.
Include affiliation of all co-authors if different from the presenting
author. |
| Text: |
Single
line spacing and full justification. |
| Paragraphs: |
Begin
each new paragraph with a single indent on the first line. Do not
leave lines between paragraphs. |
| Headings: |
These
should be in bold, font size 12, each on a separate line
and should not be indented. |
References:
(optional) |
Please
use the following method of citation if you include references:
A. Mahammadi, I. Kanfer and R.B. Walker, A capillary
zone electrophoresis (CZE) method for the determination of cyclizine
hydrochloride in tablets and suppositories. J. Pharm. Biomed. Anal.
35(1), 233-239 (2004). |
| Acknowledgements
|
Heading
– bold, size 12. Optional to include. |
|
|
| Please
note: |
- Abstracts
not meeting the above requirements may be rejected.
- The inclusion
of an e-mail address will expedite the review process.
|
Back
to Top
Abstract
Submission
Abstracts
must be submitted online (on this Website) by the presenting
author before or on 15 May 2011 as follows:
- Prepare
the abstract in MS Word, Rich Text (RTF) or Adobe PDF format as specified in
the instructions above.
- Submit
your abstract online on this Website
(select
[Participate] / [Abstract Submission] from the top menu).
You will be prompted by the congress Website system to either open
your congress profile for the first time (i.e. to get a unique congress
Access Key), OR to login to your profile using your Access Key
(i.e. if you have already registered or submitted another abstract
earlier).
(Please note that
the abstract must be submitted by the presenting author under his/her
profile, using his/her unique congress Access Key ).
- Go
to "Submit Abstracts" and
complete the information as requested on the Website form regarding
the authors, etc.
- Upload and submit your prepared
abstract in MS Word, Rich Text (RTF) or Adobe PDF format (not
Macintosh format) from your computer.
- After submission
you may use your unique congress Access Key to login and view
your submitted abstract(s) at any time and also to view its/their
status (i.e. in review/accepted/rejected and podium/poster).
All enquiries regarding
your abstract submissions can also be directed to bodensteinj@ukzn.ac.za.
Submission
by other methods
In last option scenarios (strictly and only
when electronic submissions is absolutely not possible and with motivation)
abstracts may also be submitted via e-mail.
Sample
Abstract
|
A
Novel Multi-Unit System for the Delivery of Neuroprotectants
in Parkinson’s Disease
Neha
Singh, Viness Pillay* and Michael P. Danckwerts
University of the Witwatersrand, Department
of Pharmacy and Pharmacology, 7 York Road, Johannesburg, 2193
*Correspondence: pillayvi@therapy.wits.ac.za
Purpose:
Parkinson’s Disease (PD) is
a neurodegenerative disease that affects the central nervous
system, namely the substantia nigra and leads to problems
with body movements. The need for newer and more effective
agents is consequently receiving a great deal of attention
and is being subjected to extensive research. For the purposes
of this study Nicotine has been considered as a possible model
drug that may be delivered through a novel reinforced cross-linked
multiple-unit drug delivery device that can provide prolonged
zero-order drug release kinetics.
Methods:
Preparation of gelispheres: Ionotropic
gelation was employed to formulate the gelispheres. A combination
of polymers namely Hydroxypropylcellulose (HPC), Carbopol
934 (CP) and Pectin was employed to formulate the gelispheres.
A 2%w/v solution of calcium chloride was used as the cross-linking
agent. CP was added to the cross-linking solution (Formulation
1) and to the Pectin-HPC-Nicotine mixture (Formulation 2).
The gelispheres were cured for 30 minutes and subsequently
dried under ambient conditions under a fume hood.
Drug Entrapment Tests: 50mg of drug-loaded
gelispheres were dissolved in 100mL of phosphate buffered
saline (PBS) of pH 7.4 (to simulate CSF) and thereafter agitated
at room temperature over a period of 24 hours. The solution
was subsequently analyzed using UV Spectroscopy for the presence
of Nicotine.
Drug Release Study: In vitro dissolution
studies were performed in triplicate on 100mg of drug-loaded
gelispheres which were placed in 400mL PBS maintained at 37°C.
USP 25 rotating paddle method was employed at 50 rpm. Samples
of the solution were removed at 3 hour intervals following
which they were analyzed by UV spectroscopy.
Incorporating Gelispheres into an External
Matrix: A 2:1 combination of Polyethylene oxide (PEO)
and CP was employed as the external matrix for the gelispheres.
Briefly, 300mg of the dry polymer-salt mixture was mixed with
100mg gelispheres and subsequently compressed into discs of
10mm diameter. These were subsequently analyzed for drug release
as stated above.
Results:
Results demonstrated the need for
the presence of an external matrix to further retard drug
release, as the gelispheres alone released 100% drug within
24 hours, while the presence of an external matrix delayed
release by 96 hours. Formulation 2 demonstrated superior drug
entrapment and drug release kinetics possibly due to an interaction
between Pectin and HPC. In addition, Nicotine is quite a complex
molecule with potential to interact with Pectin. This may
have led to the formation of a polymer-drug conjugate.
|
|
Back
to Top
|